Results 41 to 50 of about 42,337 (292)

Angiogenesis in myelodysplastic syndromes [PDF]

British Journal of Cancer, 1999
It is now well established that solid tumour growth depends on angiogenesis. However, less is known about the generation of new vessels in haematological malignancies and, in particular, in preleukaemic-myelodysplastic syndromes (MDS). In this study, bone marrow microvessel density (MVD) was assessed by immunohistochemistry and compared in trephine ...
G. Pruneri, F. Bertolini, D. Soligo, N. Carboni, A. Cortelezzi, P. F. Ferrucci, R. Buffa, G. Lambertenghi-Deliliers, F. Pezzella   +8 more
openaire   +4 more sources

Myelodysplastic Syndromes and Metabolism

International Journal of Molecular Sciences, 2021
Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders exhibiting ineffective hematopoiesis, dysplastic cell morphology in the bone marrow, and peripheral cytopenia at early stages; while advanced stages carry a high risk for transformation into acute myeloid leukemia (AML).
Ekaterina Balaian, Manja Wobus, Martin Bornhäuser, Triantafyllos Chavakis, Katja Sockel   +4 more
openaire   +3 more sources

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF).
Abdelrahman Saqr, Shen Cheng, Mahmoud Al‐Kofahi, Christopher Staley, Pamala A. Jacobson   +4 more
wiley   +1 more source

Clinical and genetic predictors of prognosis in myelodysplastic syndromes

Haematologica, 2014
Myelodysplastic syndromes are a collection of clonal hematopoietic disorders with a wide range of clinical manifestations and eventual outcomes. Accurate prediction of a patient’s prognosis is useful to define the risk posed by the disease and which ...
Rafael Bejar
doaj   +1 more source

Epigenetics in myelodysplastic syndromes [PDF]

Seminars in Cancer Biology, 2018
Epigenetic regulators are the largest group of genes mutated in MDS patients. Most mutated genes belong to one of three groups of genes with normal functions in DNA methylation, in H3K27 methylation/acetylation or in H3K4 methylation. Mutations in the majority of epigenetic regulators disrupt their normal function and induce a loss-of-function ...
Heuser, Michael, Yun, Haiyang, Thol, Felicitas   +2 more
openaire   +2 more sources

Therapy-related myeloid neoplasms following treatment with radioiodine

Haematologica, 2012
Background Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment.Design and Methods We retrospectively analyzed 39 patients with myeloid neoplasms following radioiodine ...
Thomas Schroeder, Andrea Kuendgen, Sabine Kayser, Nicolaus Kröger, Friederike Braulke, Uwe Platzbecker, Viola Klärner, Fabian Zohren, Detlef Haase, Michael Stadler, Richard Schlenk, Akos G. Czibere, Ingmar Bruns, Roland Fenk, Norbert Gattermann, Rainer Haas, Guido Kobbe, Ulrich Germing   +17 more
doaj   +1 more source

Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides

European Journal of Heart Failure, EarlyView.
Cancer patients presenting to the emergency department ED with dyspnoea. Among 2153 patients presenting to the ED with dyspnea, 473 (22.0%) had an active or past cancer. Acute heart failure (AHF) was the most common final diagnosis in both groups. Pneumonia and cancer‐related dyspnoea were more common in cancer patients.
Paolo Bima, Desirée Wussler, Pedro Lopez‐Ayala, Maria Belkin, Albina Nowak, Xueting Lin, Ivo Strebel, Fabiana Sgueglia, Eleni Michou, Androniki Papachristou, Laureve Chollet, Codruta Popescu, Nikola Kozhuharov, Samyut Shrestha, Gabriela Kuster, Katharina Rentsch, Arnold Von Eckardstein, Mascha Binder, Felix Mahfoud, Tobias Breidthardt, Christian Mueller   +20 more
wiley   +1 more source

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes

Haematologica, 2013
Interstitial deletion of chromosome 5q is the most common chromosomal abnormality in myelodysplastic syndromes. The catalogue of genes involved in the molecular pathogenesis of myelodysplastic syndromes is rapidly expanding and next-generation sequencing
Marta Fernandez-Mercado, Adam Burns, Andrea Pellagatti, Aristoteles Giagounidis, Ulrich Germing, Xabier Agirre, Felipe Prosper, Carlo Aul, Sally Killick, James S. Wainscoat, Anna Schuh, Jacqueline Boultwood   +11 more
doaj   +1 more source

Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques

Head &Neck, EarlyView.
ABSTRACT Background Partial laryngectomy has been well described as a management option for T1–3 laryngeal squamous cell cancers. However, there are a few case reports of partial laryngeal surgery for locally advanced thyroid carcinoma. Methods This is a case series of five patients with thyroid carcinoma (one primary and four recurrent) with laryngeal
Ella E. Hawes, Victoria E. Banuchi, Anastasios Maniakas, Jennifer R. Wang, Paul H. Graham, Julia D. Diersing, Naifa L. Busaidy, Maria E. Cabanillas, Ramona Dadu, Sarah Hamidi, Priyanka Iyer, Steven G. Waguespack, Salmaan Ahmed, Sahar Alizada, Alexandra Belcastro, Ranim Alsharif, Mimi I. Hu, Mark E. Zafereo   +17 more
wiley   +1 more source

Emerging Therapies for the Myelodysplastic Syndromes

Clinical Hematology International, 2019
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge.
Jonathan Canaani
doaj   +1 more source